| Tarhini, Ahmad |
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients |
|
|
| Active, not recruiting | 2 | 17 | US | Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation | H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated | Melanoma | 06/28 | 06/28 | | |
NCT04869137: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 26 | US | Lenvatinib Oral Product, LENVIMA, Pembrolizumab, Keytruda | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin | 09/25 | 09/26 | | |
NCT06295159: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma |
|
|
| Recruiting | 2 | 90 | US | Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Ipilimumab, Yervoy | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma | 07/27 | 07/27 | | |
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients |
|
|
| Recruiting | 2 | 29 | US | Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab | H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc. | Melanoma Stage III, Melanoma Stage IV, Inoperable Disease | 08/25 | 11/29 | | |
NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma |
|
|
| Recruiting | 2 | 32 | US | Binimetinib, Mektovi, ARRY-162, Belinostat, Beleodaq | H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Acrotech Biopharma Inc. | Metastatic Uveal Melanoma | 09/25 | 12/25 | | |
NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma |
|
|
| Recruiting | 2 | 37 | US | Pembrolizumab, Keytruda, Olaparib, AZD2281, KU-0059736, Lynparza | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Uveal Melanoma, Ocular Melanoma | 07/26 | 07/26 | | |
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma |
|
|
| Recruiting | 2 | 32 | US | ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo | H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals | Metastatic Uveal Melanoma | 10/30 | 10/30 | | |
| Recruiting | 1/2 | 316 | US | ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], GAZYVA, pembrolizumab, KEYTRUDA® | Simcha IL-18, Inc., Merck Sharp & Dohme LLC | Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High | 06/25 | 12/25 | | |
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 112 | US, RoW | SRK-181, anti-PD-(L)1 antibody therapy | Scholar Rock, Inc. | Cancer | 12/24 | 12/24 | | |
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma |
|
|
| Recruiting | 1 | 30 | US | Cemiplimab-Rwlc, Libtayo | H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | 06/27 | 06/27 | | |
NCT03114319: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 227 | Europe, Canada, Japan, US, RoW | TNO155, TNO155 in combination with EGF816 (nazartinib) | Novartis Pharmaceuticals | Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma | 05/25 | 05/25 | | |
| Completed | 1 | 91 | US | AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4 | Agenus Inc. | Advanced Cancer | 02/24 | 11/24 | | |
NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors |
|
|
| Terminated | 1 | 45 | US | KD033 (SAR445710) | Kadmon, a Sanofi Company | Solid Tumor | 12/23 | 12/23 | | |
NCT04741997: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma |
|
|
| Recruiting | 1 | 50 | US | Encorafenib Pill, Binimetinib Pill, Nivolumab | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation | 01/25 | 01/26 | | |
NCT05651828: Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma |
|
|
| Recruiting | 1 | 34 | US | Vismodegib 150 MG Oral Capsule, Erivedge | H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc. | Advanced Basal Cell Carcinoma | 12/28 | 12/29 | | |
